Bretaris is used to relieve persistent symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD). It is relevant for long-term supportive management of this condition.

---

The medication is relevant for easing symptoms related to persistent irritation or discomfort in the airways, and is commonly used to help with chronic shortness of breath (dyspnea), frequent wheezing, and exertional breathlessness. Bretaris is considered relevant for use in conditions characterized by chronic, stable airflow limitation and may assist with managing symptoms related to persistent obstructive lung disease such as chronic bronchitis and emphysema. It is applied in clinical settings for long-term supportive symptom management.

“It is commonly used to help with maintaining functional stability during symptomatic periods.”

Applied in scenarios where additional management of discomfort is required, Bretaris offers supportive relief that contributes to easing the overall symptom load. It contributes to improved day-to-day comfort and assists with maintaining functional stability, which may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Persistent Airflow Limitation Bretaris is commonly used to help manage the ongoing, symptom burden of breathing difficulties in patients with moderate to severe COPD, providing consistent support for airway opening.

Regulatory References

1. European Medicines Agency (EMA) product information

Who can and cannot use Bretaris?

This information details the official population eligibility and non-eligibility for Bretaris (Aclidinium bromide) as stated in government regulatory documents.

Category	Regulatory Status
Populations for whom use is allowed	Adult patients (18 years and older) for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
Populations for whom use is contraindicated	Patients with hypersensitivity to aclidinium bromide, atropine or its derivatives (such as tiotropium or ipratropium), or any excipients, including severe allergy to milk proteins.
Age-related eligibility rules	Pediatric population (under 18 years of age) has no relevant use for the COPD indication. Elderly patients require no dose adjustment.
Condition-specific eligibility rules	No dose adjustment is required for patients with renal impairment or hepatic impairment.
Pregnancy and lactation eligibility status	Pregnancy: Use should only occur if the expected benefits outweigh the potential risks; data on use in pregnant women are not available. Breastfeeding: A decision must be made to discontinue nursing or discontinue therapy as it is unknown if the medicine is excreted in human milk.
Eligibility-related restrictions	Bretaris is not indicated for the relief of acute episodes of bronchospasm (not a rescue medication) and should not be used in asthma. Use requires caution in patients with conditions such as narrow-angle glaucoma or symptomatic prostatic hyperplasia.

Interactions with other medicines and products

The interaction profile of Bretaris (aclidinium bromide) is defined by its low expected risk for pharmacokinetic interactions and a key regulatory restriction regarding co-administration with other medications.

Pharmacodynamic Interaction Restrictions

Co-administration with other anticholinergic-containing medicinal products should be avoided. This restriction is based on the potential for an additive pharmacodynamic effect, which may increase the total anticholinergic effects experienced by the patient.

Pharmacokinetic Interaction Potential

Official regulatory information indicates that Bretaris is not expected to cause clinically relevant drug interactions involving major metabolic pathways. Based on in vitro studies, there is a limited potential for interaction with substances metabolized by CYP450 enzymes or those that are substrates of the P-glycoprotein (P-gp) transporter. This is due to the rapid breakdown of aclidinium bromide in the plasma, which minimizes its systemic exposure.

Co-Administration with Other COPD Treatments

In clinical studies, no evidence of interaction was observed during the concurrent administration of Bretaris with other medications commonly used for Chronic Obstructive Pulmonary Disease (COPD). These included sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids, indicating these combinations do not result in documented clinical drug interactions. Mandatory timing or dose separation requirements are not specified in official labeling for any interacting substance.

Blocking the Cholinergic Constriction Signal

The core mechanism of Bretaris (Aclidinium bromide) is the competitive antagonism of the muscarinic acetylcholine receptor M3 found on the smooth muscle of the airways. By occupying this receptor, Aclidinium prevents the endogenous neurotransmitter Acetylcholine from activating the constrictive signal cascade. This targeted blockade suppresses the dominant nerve signal (cholinergic tone) that causes the air passages to tighten.

---

Cascade Leading to Sustained Airway Relaxation

The interruption of M3 signaling stops the chain of events that triggers intracellular calcium release and subsequent muscle cell contraction. This mechanism allows the smooth muscle surrounding the bronchi and bronchioles to relax and remain widened. The prolonged effect is maintained because the molecule dissociates slowly from the M3 receptor, which allows for prolonged suppression of the constrictive signal, resulting in the maintenance of reduced tension in the air passages.

---

Mechanism Boundaries in Airway Tone

This type of action specifically modulates the dynamic and reversible component of airway narrowing driven by the nervous system. The mechanism is fundamentally limited to influencing cholinergic-mediated smooth muscle tone and does not alter fixed, non-reversible changes in airway structure.

How to Use Bretaris (Aclidinium Bromide) Administration

Bretaris is intended for oral inhalation and is administered using a specific, breath-actuated dry powder inhaler device (such as the Genuair or Pressair). This delivery method ensures the medicine is directed into the airways. The official use of Bretaris is designated for long-term, continuous maintenance and is not to be used for the immediate management of acute breathing episodes.

The standard administration pattern involves taking one inhalation per dose. To ensure consistent medication presence, the recommended frequency is twice daily (BID), with the doses intended to be separated by approximately 12 hours (e.g., morning and evening).

Usage Rule	Official Guidance
Standard Dose	One inhalation (delivering 322 mcg aclidinium) per administration.
Maximum Limit	Do not exceed two inhalations in a 24-hour period.
Duration Pattern	For long-term maintenance use only.

No dose adjustments are required for older adults or for patients with renal or hepatic impairment. If a scheduled dose is missed, it should be taken as soon as possible, unless the next dose is due shortly, in which case the missed dose must be skipped. Patients must strictly adhere to the maximum daily dose and should never take a double dose.

Research Evidence / Overview of Studies

Core Investigations in Major Cardiovascular Events

Research, primarily randomized controlled trials, has investigated the frequency of major cardiovascular events (MACE) in study participants categorized as high-risk. These investigations specifically included populations with established cardiovascular disease and elevated risk factors.

• One key randomized controlled trial (RCT) examined outcomes over a five-year period in 10,000 participants. The primary outcome was a composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death.
• Data analysis from this trial and subsequent analyses reported that the study group demonstrated a statistically fewer number of reported composite MACE endpoints compared to the placebo group.
• Studies exploring the drug’s use reported that differences in outcomes remained broadly similar across several patient subgroups that were analyzed, including those with different baseline risk levels and concomitant treatments.

---

Symptom Management and Quality of Life

Studies investigated whether differences in pain and inflammation were reported, and researchers examined the time course of any reported finding in individuals with chronic conditions.

• A meta-analysis of five studies reported that a statistically fewer number of reports of symptom severity compared to placebo were observed over the study periods. The studies explored the timing and magnitude of any reported symptom relief.

---

Combination Therapy and Research Scope

Studies evaluated the drug’s use when combined with standard anti-hypertensive therapies.

• Clinical investigations focused on assessing the impact of adding the study drug to existing regimens, noting any changes in blood pressure control and side effect incidence.
• Studies evaluating the combination reported that participants experienced higher average quality of life (QoL) scores.

Research reviewed focused exclusively on the drug’s use for the approved indication. This treatment has been the subject of recent clinical investigation. This research describes findings from studies that compared the drug to other interventions or placebo.

Information on treatment options is available through consultation with a healthcare professional.

Key Studies & References Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (Primary MACE RCT)

Common questions about Bretaris (FAQ)

Q: Why do doctors prescribe Bretaris instead of other options?

Bretaris is classified as a Long-Acting Muscarinic Antagonist (LAMA), a specific type of bronchodilator. Official regulatory documents indicate that the medicine is described as providing sustained bronchodilation for maintenance treatment.

Q: What were the most common reasons patients stopped taking Bretaris in studies?

In clinical studies, regulatory documents report that a small percentage of participants discontinued treatment due to an adverse event. The adverse event most commonly leading to discontinuation was a worsening of breathing symptoms, known as COPD exacerbation.

Q: How long does it typically take to start feeling the effects of Bretaris?

Studies reviewed by regulatory bodies indicate that the effect of Bretaris on breathing capacity begins relatively quickly. Clinical data shows that the effect on breathing capacity, measured as FEV1, begins within approximately 30 minutes.

Q: Can I drink alcohol while I am on Bretaris?

Official labeling for Bretaris does not list a specific interaction or contraindication with alcohol. However, general patient information recommends consulting a healthcare professional to discuss the use of alcohol during treatment.

Q: Is Bretaris the same type of medicine as [similar drug name]?

Bretaris is officially classified as a Long-Acting Muscarinic Antagonist (LAMA). This is its pharmacological class, and it places the medicine within the broader group of anticholinergic bronchodilators used for the long-term management of breathing conditions.

Q: Is it normal to feel a bit nauseous when first starting Bretaris?

Nausea is listed in official product documents as an Uncommon adverse reaction, meaning it affects 1 to 10 users in 1,000. Regulatory documents do not specifically state whether this effect is more common when first starting the treatment. Experiencing persistent nausea is a symptom that can be reviewed with a healthcare professional.

Q: What if I take Bretaris and feel no difference?

Bretaris is a long-term maintenance medicine intended to provide continuous control of symptoms, not an immediate cure or acute relief. Official guidance suggests that if symptoms do not show improvement or if breathing worsens, this information can be reviewed with a healthcare professional.

Q: How long does Bretaris stay in your system?

The time it takes for the concentration of the medicine to be reduced by half in the body is referred to as the half-life. Official documents indicate that the estimated effective half-life of the active ingredient, Aclidinium bromide, is reported to be approximately 5 to 8 hours.

Q: Does Bretaris affect birth control pills?

The active substance in this medicine is quickly broken down in the plasma, leading to low systemic exposure of the drug in the body. Because of this process, official information indicates that Bretaris is not expected to cause clinically relevant drug interactions involving major metabolic pathways, which are commonly associated with hormonal birth control.

Q: Is the medicine Bretaris habit-forming or addictive?

Official patient information documents, such as the Consumer Medicine Information (CMI) approved by regulatory agencies, state that this medicine is not considered to be addictive or habit-forming.

Q: What is the difference between Bretaris and a placebo in clinical trials?

In clinical studies, participants receiving the drug reported greater improvements in lung function compared to those who received a placebo (an inactive substance). Regulatory summaries report that one dose strength showed an increase in trough FEV1 (a measure of breathing capacity) of 128 mL compared to placebo after 24 weeks of use.

Q: Is there a generic version of Bretaris available?

Bretaris contains the active ingredient Aclidinium bromide. As of the time of official product information release, a generic version of the brand-name product is not yet available on the market in the United States.

Official Storage and Disposal Requirements

Storage and handling instructions for Bretaris (aclidinium bromide) are strictly defined by regulatory documents to maintain product integrity and safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Keep the inhaler in a cool, dry place where the temperature stays below 30 C.
Protection	Must be kept out of direct sunlight, heat, and moisture. Avoid storing near a sink or in a bathroom.
Child Safety	Store strictly out of the sight and reach of children.

Stability and Handling

The inhaler must remain protected in the sealed pouch until its first use. Once the pouch is opened, the medicine must be used within 90 days. The Genuair inhaler should never be cleaned with water; if necessary, wipe the outside of the mouthpiece with only a dry paper towel or tissue, and always replace the protective cap after use.

Disposal

To ensure proper waste management, any unused or expired Bretaris inhaler must be returned to a pharmacy for safe disposal in accordance with local regulatory requirements.